FY2024 EPS Estimates for Opthea Limited Lowered by Analyst (NASDAQ:OPT)

Opthea Limited (NASDAQ:OPT) – Stock analysts at Leerink Partnrs decreased their FY2024 earnings estimates for Opthea in a research report issued to clients and investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($2.15) for the year, down from their previous estimate of ($1.70). The consensus estimate for Opthea’s current full-year earnings is ($2.46) per share. Leerink Partnrs also issued estimates for Opthea’s FY2025 earnings at ($1.20) EPS and FY2026 earnings at ($0.90) EPS.

Opthea Stock Down 1.8 %

OPT stock opened at $3.83 on Friday. The company has a fifty day moving average price of $3.47 and a 200-day moving average price of $2.67. Opthea has a 52-week low of $1.60 and a 52-week high of $4.42.

Institutional Investors Weigh In On Opthea

Several large investors have recently modified their holdings of OPT. Barclays PLC acquired a new stake in shares of Opthea during the first quarter worth $26,000. Regal Partners Ltd increased its position in shares of Opthea by 1.0% during the second quarter. Regal Partners Ltd now owns 2,914,577 shares of the company’s stock worth $8,161,000 after buying an additional 29,777 shares during the period. Finally, OLD Mission Capital LLC acquired a new stake in shares of Opthea during the fourth quarter worth $36,000. 55.95% of the stock is currently owned by institutional investors and hedge funds.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.